Area of research
Reproductive Medicine · Obstetrics and Gynecology
Research interest
Research interests include Ovarian cancer diagnosis and treatment, PARP inhibition in cancer therapy, Endometrial and Cervical Cancer Treatments, and Cancer-related molecular mechanisms research.
Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS‐1): A multicenter, randomized, double‐blind, placebo‐controlled phase 3 trial
Senaparib as first-line maintenance therapy in advanced ovarian cancer: a randomized phase 3 trial
Fuzuloparib as maintenance therapy among patients with advanced ovarian cancer after a response to first-line platinum-based chemotherapy: Results from a randomized, placebo-controlled, phase III trial
453 Senaparib maintenance in newly diagnosed advanced ovarian cancer: FLAMES study
Multi-omics characterization of silent and productive HPV integration in cervical cancer
Pegylated liposomal doxorubicin and carboplatin versus paclitaxel and carboplatin as first-line treatment for Chinese patients with ovarian cancer: A multi-center, randomized, open-label trial.
Chinese expert consensus on the clinical applications of aminolevulinic acid-based photodynamic therapy in female lower genital tract diseases (2022)
A novel attention-guided convolutional network for the detection of abnormal cervical cells in cervical cancer screening
Targeting DNA Repair Response Promotes Immunotherapy in Ovarian Cancer: Rationale and Clinical Application
Identifying Potential Markers for Monitoring Progression to Ovarian Cancer Using Plasma Label-free Proteomics
Organoid of ovarian cancer: genomic analysis and drug screening
Therapeutic applications of PARP inhibitors in ovarian cancer
Integrated analysis of a competing endogenous RNA network reveals an 11-lncRNA prognostic signature in ovarian cancer
Circular RNA (hsa_circ_0051240) promotes cell proliferation, migration and invasion in ovarian cancer through miR-637/KLK4 axis
Immunoscore system combining CD8 and PD-1/PD-L1: A novel approach that predicts the clinical outcomes for cervical cancer
Phase I Pharmacokinetic Study of Niraparib in Chinese Patients with Epithelial Ovarian Cancer
A Prognostic Nomogram for Cervical Cancer after Surgery from SEER Database
Upregulation of miR‐874‐3p and miR‐874‐5p inhibits epithelial ovarian cancer malignancy via SIK2
S100A7 Regulates Ovarian Cancer Cell Metastasis and Chemoresistance Through MAPK Signaling and Is Targeted by miR-330-5p
Selection of small plasma peptides for the auxiliary diagnosis and prognosis of epithelial ovarian cancer by using UPLC/MS‐based nontargeted and targeted analyses
Long non-coding RNA ZFAS1 interacts with miR-150-5p to regulate Sp1 expression and ovarian cancer cell malignancy
A Comprehensive Analysis of Metabolomics and Transcriptomics in Cervical Cancer
Metabolic profiling and novel plasma biomarkers for predicting survival in epithelial ovarian cancer
Platelet-Derived Growth Factor D Is a Prognostic Biomarker and Is Associated with Platinum Resistance in Epithelial Ovarian Cancer
MiR-381 inhibits epithelial ovarian cancer malignancy via YY1 suppression
KIAA0101, a target gene of miR-429, enhances migration and chemoresistance of epithelial ovarian cancer cells
Correlation of Collagen Triple Helix Repeat Containing1 Overexpression with Lymph Node and Peritoneal Metastasis in Epithelial Ovarian Cancer
miR-211 suppresses epithelial ovarian cancer proliferation and cell-cycle progression by targeting Cyclin D1 and CDK6
Long noncoding RNA CCHE1 promotes cervical cancer cell proliferation via upregulating PCNA
DLL4 as a predictor of pelvic lymph node metastasis and a novel prognostic biomarker in patients with early-stage cervical cancer